Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  3,023 results for ""Canagliflozin""

Your Filters

Publisher : wiley-blackwell
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial.

  • Authors : Cardoza K; Department of Medicine, Cedars-Sinai Medical Center, California, Los Angeles, USA.; Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.

Subjects: Canagliflozin*/Canagliflozin*/Canagliflozin*/therapeutic use ; Canagliflozin*/Canagliflozin*/Canagliflozin*/adverse effects ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Sep; Vol. 26 (9), pp. 3530-3540. Date of Electronic Publication: 2024 Jun 19.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis.

Subjects: Canagliflozin*/Canagliflozin*/Canagliflozin*/therapeutic use ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/metabolism

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Sep; Vol. 26 (9), pp. 4060-4068. Date of Electronic Publication: 2024 Jul 16.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

Ethnic disparities in cardiovascular and renal responses to canagliflozin between Asian and White patients with type 2 diabetes mellitus: A post hoc analysis of the CANVAS Program.

  • Authors : Chen X; Department of Pharmacy, Shenzhen Hospital of Southern Medical University, Shenzhen, China.; Hou X

Subjects: Canagliflozin*/Canagliflozin*/Canagliflozin*/adverse effects ; Canagliflozin*/Canagliflozin*/Canagliflozin*/therapeutic use ; Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/epidemiology

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Mar; Vol. 26 (3), pp. 878-890. Date of Electronic Publication: 2023 Nov 30.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes.

  • Authors : Chen AX; Cardiovascular Program, The George Institute of Global Health, University of New South Wales, Sydney, Australia.; Sydney Medical School, University of Sydney, Sydney, Australia.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Canagliflozin*/Canagliflozin*/Canagliflozin*/therapeutic use

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Oct; Vol. 26 Suppl 5, pp. 5-13. Date of Electronic Publication: 2024 Jul 22.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

Pioglitazone reduces serum ketone bodies in sodium-glucose cotransporter-2 inhibitor-treated non-obese type 2 diabetes: A single-centre, randomized, crossover trial.

  • Authors : Yang M; Division of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Laboratory of Endocrinology& Metabolism, and Ministry of Education Key Laboratory of Vascular Aging, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Subjects: Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/blood

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Aug; Vol. 26 (8), pp. 3137-3146. Date of Electronic Publication: 2024 May 03.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial.

  • Authors : Razaghizad A; Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.; Department of Medicine, McGill University, Montreal, Quebec, Canada.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/epidemiology

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2024 Nov; Vol. 26 (11), pp. 5025-5035. Date of Electronic Publication: 2024 Sep 20.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial.

  • Authors : Li JW; The George Institute for Global Health UNSW Sydney Sydney Australia.; Department of Cardiology, Xinqiao Hospital Army Military Medical University Chongqing China.

Subjects: Canagliflozin*/Canagliflozin*/Canagliflozin*/therapeutic use ; Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/epidemiology ; Cardiovascular Diseases*/Cardiovascular Diseases*/Cardiovascular Diseases*/prevention & control

  • Source: Journal of the American Heart Association [J Am Heart Assoc] 2022 Aug 16; Vol. 11 (16), pp. e025045. Date of Electronic Publication: 2022 Aug 05.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101580524 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin Antagonizes Salt-Sensitive Hypertension Through Modifying Transient Receptor Potential Channels 3 Mediated Vascular Calcium Handling.

  • Authors : Zhao Y; Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Daping Hospital Army Medical University, Chongqing Institute of Hypertension Chongqing China.; Li L

Subjects: Canagliflozin*/Canagliflozin*/Canagliflozin*/pharmacology ; Canagliflozin*/Canagliflozin*/Canagliflozin*/therapeutic use ; Hypertension*/Hypertension*/Hypertension*/chemically induced

  • Source: Journal of the American Heart Association [J Am Heart Assoc] 2022 Aug 02; Vol. 11 (15), pp. e025328. Date of Electronic Publication: 2022 Jul 29.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101580524 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial.

  • Authors : Barraclough JY; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.; Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

Subjects: Canagliflozin*/Canagliflozin*/Canagliflozin*/adverse effects ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Peripheral Arterial Disease*/Peripheral Arterial Disease*/Peripheral Arterial Disease*/complications

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2022 Jun; Vol. 24 (6), pp. 1072-1083. Date of Electronic Publication: 2022 Mar 07.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

Mediators of the effects of canagliflozin on N-terminal pro-brain natriuretic peptide concentration: An exploratory mediation analysis of the randomized CANDLE trial.

Subjects: Canagliflozin*/Canagliflozin*/Canagliflozin*/adverse effects ; Mediation Analysis*; Biomarkers

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2022 May; Vol. 24 (5), pp. 962-965. Date of Electronic Publication: 2022 Feb 21.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
  • 1-10 of  3,023 results for ""Canagliflozin""